ArticleNeoplasia (New York, N.Y.)2015
In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment.
Article in Neoplasia (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 106 citations in OpenAlex.
- Article
- Fluorescence Lifetime Imaging Techniques-A Review on Principles, Applications and Clinical Relevance.Journal of biophotonics · 2025Review
- Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids.Cancer research · 2025Article
- Optical diagnostics of liver tumors using an autofluorescence lifetime probe.Biomedical optics express · 2025Article
- Cellpose as a reliable method for single-cell segmentation of autofluorescence microscopy images.Scientific reports · 2025Article
- Accelerating biopharmaceutical cell line selection with label-free multimodal nonlinear optical microscopy and machine learning.Communications biology · 2025Article
- Differentiation of Tumors of the Upper Respiratory Tract Using Optical Metabolic Imaging.Lasers in surgery and medicine · 2025Article
- Widefield frequency-domain autofluorescence lifetime imaging for detecting breast cancer in murine xenograft tumor tissues.Journal of biomedical optics · 2025Article
- Article
- Evaluation of Cellpose segmentation with sequential thresholding for instance segmentation of cytoplasms within autofluorescence images.Computers in biology and medicine · 2024Article
- Insights into metabolic heterogeneity of colorectal cancer gained from fluorescence lifetime imaging.eLife · 2024Article
- Cellpose as a reliable method for single-cell segmentation of autofluorescence microscopy images.bioRxiv : the preprint server for biology · 2024Article
- To label or not: the need for validation in label-free imaging.Journal of biomedical optics · 2024Review
- Monitoring the Intracellular pH and Metabolic State of Cancer Cells in Response to Chemotherapy Using a Combination of Phosphorescence Lifetime Imaging Microscopy and Fluorescence Lifetime Imaging Microscopy.International journal of molecular sciences · 2023Article
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- Light-sheet autofluorescence lifetime imaging with a single-photon avalanche diode array.Journal of biomedical optics · 2023Article
- Label-free, multi-parametric assessments of cell metabolism and matrix remodeling within human and early-stage murine osteoarthritic articular cartilage.Communications biology · 2023Article
- Light sheet autofluorescence lifetime imaging with a single photon avalanche diode array.bioRxiv : the preprint server for biology · 2023Article
- Article
- Spatial Alignment of Organoids Tracking Subclonal Chemotherapy Resistance in Pancreatic and Ampullary Cancer.Bioengineering (Basel, Switzerland) · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Subpopulations of cells that escape anti-cancer treatment can cause relapse in cancer patients. Therefore, measurements of cellular-level tumor heterogeneity could enable improved anti-cancer treatment regimens. Cancer exhibits altered cellular metabolism, which affects the autofluorescence of metabolic cofactors NAD(P)H and FAD. The optical redox ratio (fluorescence intensity of NAD(P)H divided by FAD) reflects global cellular metabolism. The fluorescence lifetime (amount of time a fluorophore is in the excited state) is sensitive to microenvironment, particularly protein-binding. High-resolution imaging of the optical redox ratio and fluorescence lifetimes of NAD(P)H and FAD (optical metabolic imaging) enables single-cell analyses. In this study, mice with FaDu tumors were treated with the antibody therapy cetuximab or the chemotherapy cisplatin and imaged in vivo two days after treatment. Results indicate that fluorescence lifetimes of NAD(P)H and FAD are sensitive to early response (two days post-treatment, P<.05), compared with decreases in tumor size (nine days post-treatment, P<.05). Frequency histogram analysis of individual optical metabolic imaging parameters identifies subpopulations of cells, and a new heterogeneity index enables quantitative comparisons of cellular heterogeneity across treatment groups for individual variables. Additionally, a dimensionality reduction technique (viSNE) enables holistic visualization of multivariate optical measures of cellular heterogeneity. These analyses indicate increased heterogeneity in the cetuximab and cisplatin treatment groups compared with the control group. Overall, the combination of optical metabolic imaging and cellular-level analyses provide novel, quantitative insights into tumor heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.